It is over 10 years since the first ACPGBI Position Statement on the management of anal fistula was published in 2007. This second edition is the result of scrutiny of the literature published during this time; it updates the original Position Statement and reviews the published evidence surrounding treatments for anal fistula that have been developed since the original publication.
Introduction
Anal fistula remains a perplexing condition for the colorectal surgeon. The first ACPGBI Position Statement on this condition was published in 2007 [1] and was developed after reviewing the literature on this subject spanning many decades. Strength of evidence and guidelines on management were drawn up, but in many instances the level of evidence used to produce recommendations was deemed to be low. In the years following that publication, the literature on anal fistula has expanded, both with regard to our understanding of its aetiology (still far from confirmed) and its management, a flurry of new surgical techniques have become available and there is greater understanding of treatments that were emerging at the time of publication of the first position statement.
This second Position Statement addresses the information that has become available since the first version and updates guidelines on the management of anal fistula. This Position Statement should be read in conjunction with the original paper for a complete picture of the literature on which both statements are based.
Methodology
This Position Statement is based on evidence obtained from an extensive review of the literature. The authors concentrated on publications after 2005, as the literature prior to that date was reviewed in the original Position Statement. Organized searches of the Cochrane Database, PubMed, MEDLINE and Embase were performed using keywords relevant to each section of this Position Statement. Searches were limited to articles published in English, with a few exceptions. Additional publications were retrieved from references cited in articles identified from the primary search of the literature. Relevant papers were retrieved and studied by members of the writing committee and incorporated into this review. All evidence was classified according to an accepted hierarchy of evidence and recommendations graded A to C on the basis of the level of associated evidence and/or noted as Good Practice and/or part of NICE/SIGN recommendation or Rapid Technology Appraisal (Table 1) [2] .
This Position Statement is presented in sections dealing with aspects of pathology, diagnosis and treatment. The evidence is briefly summarized, where relevant, under the heading 'Findings' and this is followed where relevant by 'Recommendations'.
Aetiology
The crypto-glandular theory espoused by Eisenhammer [3] and Parks [4] remains the most plausible explanation for the initiating event in most cases of idiopathic anal sepsis, and is widely accepted. This theory proposes that sepsis originates as an infection in an obstructed anal gland, usually lying in the intersphincteric space.
Mitalas et al. [5] performed histological studies on the fistula track in a series of nine patients with chronic fistula undergoing exploration of the intersphincteric space. None of the tracks contained evidence of anal gland tissue with mucin-producing cells. However, this does not disprove the theory, as it is quite plausible that glandular epithelium was obliterated during the original septic process. Whereas there has not been any recent publication confirming this theory, equally there has not been a publication proposing a more plausible explanation. Naldini et al. [6] performed endoanal ultrasound scans on 175 patients with a chronic anal fissure. They demonstrated an intersphincteric fistula in 91 (53%) patients and a transsphincteric fistula in 21 (12%) patients. The relevance of this finding is uncertain. Whilst it suggests a possible alternative aetiology for an anal fistula, its relevance is more likely to be an explanation for chronicity of an anal fissure. Why some people are more prone to anal sepsis remains unexplained. Smoking within the last year seems to double the risk of anal sepsis, but this effect disappears 5 years after cessation of smoking [7] . What is less clear is the explanation for persistence of the sepsis with formation of a fistula.
Anal abscesses are a common surgical emergency, usually dealt with simply, by adequate incision and drainage. A recent study examining national hospital activity data puts the incidence of anal abscess at 20.2 per 100 000 population, although the actual incidence is likely to be higher as these data do not include patients treated in the community [8] . Whilst the cryptoglandular theory assumes that an anal fistula has arisen from the spread of infection from an anal gland, the rate of fistula formation following presentation with an anal abscess is low. Two recent series have reported similar findings, with only a third of patients presenting with an abscess going on to form an anal fistula. Furthermore, neither study identified any associated features that might have increased the risk of fistula formation, which was lower in diabetic patients [9, 10] . A lower rate of 15.5% for fistula formation following an acute anal abscess has been calculated from hospital activity data [8] , although this only included patients undergoing surgery for an anal fistula and it is likely that the overall rate is higher as patients not seeking further medical attention would not have been captured by this data set. Why some patients go on to establish a fistula remains uncertain; possible reasons include persistent sepsis, epithelialization of the track and hormone-mediated host response. Traditionally it has been assumed that persistence of sepsis drives fistula formation. However, earlier studies have shown a paucity of organisms in a fistula track [11, 12] and more recent studies using molecular techniques have shown a lack of bowel-related organisms in the fistula track. Tozer et al. [13] used in situ hybridization to study the microflora of 18 idiopathic (cryptoglandular) fistulas. Surprisingly, bacteria were not found in close association with the luminal surface of any fistula track. Similarly, in a series of 10 patients with transsphincteric fistulas, van Onkelen et al. [14] failed to identify bacteria in the fistula track using 16S rRNA sequencing in nine patients. However, immunohistochemistry revealed the presence of bacterial-derived proinflammatory peptidoglycans in all bar one fistula, with evidence of host response in 6 out of 10. This raises the possibility that fistula formation and persistence represent a host response to bacterial cell wall-derived peptidoglycans. It has been suggested (but with no evidence to confirm this) that cell wall lipopolysaccharides activate proinflammatory cytokine production, such as tumour necrosis factor a (TNFa), which could be enhanced by testosterone and inhibited by oestrogen, providing an explanation for the lower incidence of anal fistulas in women [15] . Epithelialization of the track has been hypothesized as a cause for persistence of an anal fistula, but it remains uncertain whether this is of primary aetiological importance or a secondary phenomenon. van Koperen et al. [16] examined 18 fistula tracks and demonstrated epithelialization in 15 patients, mostly around the internal opening. However, this series only included patients with a low fistula undergoing fistulotomy. Mitalas et al.
[5] performed a similar study but on 44 patients with a higher fistula involving the external sphincter. Epithelialization of the external part of the track was observed in 11 of 44 (25%) and of the intersphincteric part of the track in 2 of 11 (22%). Thus, epithelialization is uncommon within more complex fistulas.
Another conundrum is the mechanism by which sepsis spreads around the anal canal to form fistulas of differing complexity. Whilst it is easy to envisage infection spreading along paths of least resistance, such as the intersphincteric space or circumferentially in the ischio-rectal fossas, it is more difficult to explain the spread of sepsis through the external sphincter to form a transsphincteric fistula and to provide a logical explanation as to why some fistulas involve little sphincter muscle and others involve most of the external sphincter. A plausible explanation is that infection follows fibres of the longitudinal muscle penetrating the external sphincter, but this is by no means proven. Surgical dogma assumes that the 'deep postanal space' is critical to the spread of sepsis around the anus, and thus the key to eradicating a fistula was thought to be adequate drainage of this space, as well as control of the primary track. However, what constitutes the 'deep postanal space' is disputed, with some going as far as to question whether it exists as a distinct entity [17, 18] . Recent radiological and anatomical studies suggest there are several potential, or actual, spaces around the anal sphincters that are likely to be important in the spread of infection. To confuse the issue further, some of these 'spaces' cannot be identified in the normal anal canal and only become apparent once sepsis develops and localizes to that area [18] [19] [20] [21] [22] .
Imaging
Many imaging modalities are used in the investigation of anal fistulas, with some subtle refinements in techniques emerging over the last 10 years. Imaging methods include contrast fistulography, anal ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT). Anal ultrasound may be carried out with or without threedimensional reconstruction and with or without ultrasound contrast. MRI has been used with a pelvic phased array coil, an endoanal receiver coil and with or without intravenous contrast, and most recently with assessment of magnetization transfer. Each of these will be reviewed and compared and recent evidence presented.
Fistulography

Finding
Fistulography provides only very limited information on fistula anatomy. (Level III)
Recommendation
Fistulography has been superseded by other imaging modalities in the assessment of cryptogenic anorectal sepsis. (Grade B) Fistulography involves the injection of water-soluble contrast media directly into an external opening of a fistula. This technique is of historical interest and has been superseded by other imaging techniques. No new information to support the use of fistulography has emerged.
Computed tomography
Findings
CT is inferior to MRI in the assessment of anal fistula, but newer techniques can provide useful information in selected patients. (Level III)
Recommendation
Thin-slice spiral CT may be helpful when MRI is either not available or is contraindicated. (Grade C) CT scanning is inferior to MRI in its ability to differentiate between fibrosis and active disease and so has limited value, except when assessing pelvic causes for extrasphincteric tracks. Multiplanar imaging using thinslice spiral CT and intravenous contrast may be helpful in cases where MRI is either not available or is poorly tolerated, but the full extent of tracks may be underreported due to failure to fill with contrast or plugging due to debris [23] . Whilst CT probably has similar sensitivity to MRI for the detection of perianal abscesses, its role in the assessment of complex anal sepsis is limited.
Anal endosonography
Findings
Endoanal ultrasound has an established role in the assessment of anal fistulas. (Level IIa)
Recommendations
Anal endosonography (ultrasound) may be the first line investigation for patients with an anal fistula that is suspected to be complex. Patients with recurrent fistula may benefit from anal endosonography, but MRI will also be required. (Grade B) Anal endosonography and perineal sonography are useful adjuncts to the assessment of perianal Crohn's disease. (Grade C) Anal endosonography, using higher-frequency transducers and volume image acquisition, is an established investigation for anal sepsis. When this technique is used by enthusiasts to assess anal sepsis similar accuracy can be achieved to assessment by endocoil MRI, with an accuracy of over 80% [24] and near 100% concordance with surgery for simple cases and 68% for high fistulas [25] . The height and type of fistula seen on ultrasound compares well with the findings at examination under anaesthesia (EUA; 91% accuracy for type and 92% accuracy for classification of 'high' or 'low') [26, 27] .
Hydrogen peroxide infused into the external opening of a fistula track acts as an ultrasonic contrast medium to exaggerate the track and abscesses due to the formation of the hyper-reflective gas bubbles. This increases the accuracy and detail of the fistula tracks imaging [28] , and may be very helpful for the delineation of supra-levator sepsis, which is difficult to locate on clinical examination alone [26] . However, peroxide may have limited additional benefit over and above that of multiplanar ultrasound [29] or noncontrasted trans-perineal scanning [30] . Other ultrasonic contrast agents (e.g. Levovist) have been used [31] but not widely adopted because of the low cost and easy availability of peroxide and no additional benefit being seen with the more expensive agent.
Accurate assessment of the site of the internal opening is dependent upon the criteria used for ultrasonic definition [32] : budding of sepsis in the intersphincteric space towards the lumen, penetration of the internal sphincter and, finally, whether a clear track is seen all the way through the internal sphincter and into the lumen [33] . Peroxide enhancement may increase the detection of internal openings and correct fistula classification to above 80% [24, 33, 34] .
In recent years there has been significant interest in assessing Crohn's anal fistulation with ultrasound. Detection of the persistence of an internal opening on anal ultrasound after anti-TNFa treatment for Crohn's perianal sepsis may predict recurrence [35] and biological treatment guided by the findings of anal ultrasound may be beneficial [36] ; treatment directed by ultrasound findings improves the success of fistula surgery [37] and reduces recurrences in a similar way to MRI [38] . An endosonographic classification of perianal Crohn's disease has been developed, which in a large series led to a change in management in just under half of the 150 cases reviewed [39] . The endosonographic differences in appearances between Crohn's fistulas and cryptogenic sepsis have been detailed, with wider branched tracks and the presence of debris typical in Crohn's fistulas [40] . The mean greyscale of a track on endosonography may also be positively correlated with the perianal Crohn's disease activity index and assessment of fistula drainage in Crohn's disease [41] .
The alternative approach of trans-perineal ultrasound has been used to assess anal fistulas with an accuracy of up to 86% for the detection of internal fistula openings, both with Crohn's disease [42] and idiopathic fistulation [43] . Furthermore, transvaginal scanning may prove to be a useful adjunct to anal scanning for recto/ano-vaginal fistulation, with 100% positive predictive value for simple fistulas and 90% for more complex cases [44] . 
Magnetic resonance imaging
Recommendation
MRI should be considered in any primary fistula deemed after clinical or endosonographic assessment to be complex. It should also be considered in patients with a recurrent anal fistula. (Grade A) Magnetic resonance imaging is accepted as the 'gold-standard' for the assessment of anal sepsis [1] . Indeed, where there is sepsis detected on MRI but not at EUA, MRI predicts recurrence of sepsis. Thus MRI improves clinical assessment by detecting previously missed secondary extensions and correctly assessing the level of fistula with respect to the sphincter complex [45] . This may be further enhanced with novel threedimensional modelling systems to show the full extent of the sepsis in relation to the anal sphincter complex
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 3), 5-31 [46] . The use of endocoils to improve resolution has been supplanted by the use of pelvic phased array coils, particularly where more widely extensive sepsis or supralevator sepsis is suspected [47, 48] . It has been suggested that observer agreement for the reporting of complex sepsis using MRI is only good in expert centres, making standardization of the slice planes vital [49] , although expertise can be rapidly attained [50] with directed education.
Independently of the use of pelvic phased array coils, variation exists between units in the sequences used to obtain images and whether or not contrast agents are used. Rectal gadolinium-DTPA (diethylenetriamine penta-acetic acid) has been used to help to identify tracks, with limited benefit [51, 52] , and saline has been infused into tracks [53] . The insertion of a rectal balloon [54] during scanning may improve the detection of internal openings, although none of these techniques has been widely adopted. Intravenous gadolinium-DTPA is widely used to provide dynamic contrast enhanced MRI (DCEMRI) [55, 56] with equivalent benefit to images obtained by short tau inversion recovery (STIR) sequences [57] . The use of contrast aids in the differentiation between nonenhancing healed tracks and active disease that enhances. Spencer et al. [56] directly compared sequences to ascertain those that were most helpful. T1-weighted sequence scans show anatomical detail together with sinuses and fistula tracks as hypointense structures, although T2 scans provide better signal differentiation between active disease and fibrosis from inactive tracks. STIR sequences are widely used and considered by many to be superior to T1-or T2-weighted scans for the detection and delineation of sepsis [51, 58, 59] . These have the advantage of suppressing the relatively high signal from fat in the ischio-anal fossa, and so highlighting sepsis [51] . It has been suggested that STIR sequence scanning may not be able to detect small abscesses that are seen on DCEMRI with T2-weighted axial images [55, 56] , but may be better for the detection of internal openings, especially when combined with endoanal receiver coils [59] . An alternative to STIR sequence scanning is using T2-weighted scans with spectral fat saturation inversion recovery (SPIR); when these two techniques were compared, however, no added advantage was found with SPIR and sphincter detail was better with STIR [60] .
One drawback of using intravenous gadolinium is the rare complication of nephrogenic systemic fibrosis: the use of diffusion-weighted MR avoids this, although at the cost of reduced tissue detail [61, 62] . Further developments using magnetization transfer scanning may offer an alternative to contrast scans [63] . However, diffusion-weighted scans may be able to assess fistula activity to produce an 'apparent diffusion coefficient map' [64] .
The slice orientation is crucial irrespective of the sequences used for obtaining images. An initial T2-weighted sagittal scan should be obtained to orientate the pelvis such that further axial and coronal scans can be performed perpendicular and parallel to the long axis of the anal canal. The most useful planes are axial and coronal [53, [65] [66] [67] ; scans orientated in the sagittal plane are of limited value unless ano-vaginal fistulation is suspected [68] or in distinguishing from a retro-rectal cyst, with its characteristic appearance. There is a learning curve for the interpretation of MRI, with an increase in correct interpretation of up to 50% with experience [65] . Whilst initial agreement in scan interpretation is acceptable (K a = 0.7, good agreement) [59] , this can improve to K a = 0.92 with a short period of directed training [50] .
The use of MRI may predict recurrence of fistula disease. Where EUA fails to find and treat sepsis suggested on imaging, the sepsis often recurs, with the recurrence located at the site predicted by the preoperative imaging [69, 70] . In addition, MRI classification of fistulas into simple and complex is able to predict the chance of recurrence much more accurately than EUA alone (positive predictive value 73% vs 57%) [71] . When a surgeon always acts on the result of preoperative MRI, then the recurrence rate for complex fistulas is 16%, compared with 57% where the results of imaging are disregarded [72] . It has been suggested that preoperative MRI assessment has the potential to alter surgical practice in up to 10% of cases if used prospectively for primary fistulas [73] and 21% if used in a mixed population of primary and secondary fistulas and patients with Crohn's disease [74] .
Several groups have devised grading systems based on MRI. The St James' system relates to the fistula anatomy [75] and shows good concordance with surgical findings [76] . Van Assche et al. [77] have developed a MRI scoring system which includes assessment of the type and number of tracks, the presence and type of extensions, collections and rectal wall thickening and the signal intensity on T2-weighted scans. This latter scoring system has been criticized for being insensitive to changes in clinical state because the various factors which make up the score do not always change concordantly with each other. Clinical and radiological evaluation in patients with Crohn's anal fistula treated with biological agents has shown that the latter lags behind the former by 12 months [78] . Nevertheless clinical improvement is mirrored by improvement in MRI appearances up to 1 year [79, 80] and MRI may be valuable in predicting those patients who will relapse following treatment with anti-TNF treatment [81] ; studies evaluating the importance of changes in the volume of the fistula track and T2 signal intensity in predicting relapse are under way.
MRI is not always well tolerated, it is not universally available and, when compared with anal endosonography, it is time-consuming. In general use, MRI is probably superior to anal ultrasound, with concordance with surgery for ultrasound of 80% and MRI 90% [65, [67] [68] [69] 82, 83] . Ultrasound may be better at locating internal openings than non-endocoil MRI [82] , but it does have the drawback of not being possible in the presence of canal stenosis [84] , and there are difficulties in differentiating old tracks from new sepsis, and misinterpretation of intersphincteric sepsis as transsphincteric because of acoustic shadowing [85] . The role of anal ultrasound in assessing anorectal fistulation is uncertain; some report equal value with MRI (endocoil) [86] whilst others suggest limited value other than to demonstrate combined sphincteric defects [87] .
In summary, when comparing the different methods of imaging anorectal sepsis it is important to concentrate on the questions that need to be addressed, not forgetting that not all anal fistulas need investigation as the majority are primary, simple and low and can be fully assessed clinically and treated with surgery. Anal ultrasound has been shown to be able to differentiate between complex and simple sepsis [88] [89] [90] [91] .
Clearly not all patients need MRI, but there is strong evidence for the value of MRI assessment to direct surgery for recurrent fistulas. Surgery directed by preoperative MRI has a recurrence rate of 16% compared with surgery where MRI is not acted upon (recurrence rate 57%) [72] . Primary cases that are suspected to be complex should have anal ultrasound scanning where local expertise exists, and if features of complex fistulation or secondary extensions are present then MRI should be obtained. All recurrent fistulas, except those with clearly simple recurrence on anal ultrasound, should have MRI. Sequences used should include T1 images to give details of sphincter anatomy and scans with either fat suppression (STIR, SPIR) or dynamic contrast enhanced scans (DCEMRI). The scans should be orientated along and orthogonal to the long axis of the anal canal (and not the long axis of the body), facilitated by a T2 scout sagittal scan in the mid coronal position. Axial and coronal scans are of most benefit although sagittal images are of use in cases of ano/ rectovaginal fistulation. Recent scoring and grading systems may prove useful in following response to biological treatment in Crohn's fistulas, and MRI images should be used to guide surgery at the time of EUA.
Treatment
Surgery remains the mainstay of treatment of a nonCrohn's anal fistula, the aim being to cure the fistula while at the same time preserving anal sphincter function. Various surgical approaches remain in use, indicating that there is no ideal procedure applicable to every patient. Since publication of the first edition of this Position Statement [1] a number of new, minimally invasive approaches to surgical treatment have emerged. Informed consent involves discussing surgical options and their likely outcome with a patient, as well as the consequences of any complications. This should include discussion about the risk of recurrence/persistence of the fistula as well as alteration in anal control. A fistula can vary in complexity from being simple, involving only a small proportion of the anal sphincter, to complex, with multiple tracks involving more of the anal sphincter. The surgeon should be able to identify the degree of complexity of the fistula and plan surgery accordingly. Complex fistulas should be treated by an experienced surgeon, particularly when they are associated with Crohn's disease. (Level of evidence: Level IV, Grade GP).
Fistulotomy
Findings
Fistulotomy has an extremely high (95%+) cure rate, as long as all tracks are dealt with. Sphincter division, even for low and intersphincteric fistulas, carries approximately a one in three chance of inadvertent loss of flatus and slight passive soiling, largely determined by internal sphincter division. Whilst division of the anorectal ring will lead to frank faecal incontinence, in expert hands laying open larger amounts of the external sphincter (preserving at least 2 cm of cephalad sphincter) has outcomes similar to those after laying open of a low anal fistula. (Level III)
Recommendations
As a general rule, fistulotomy results in a reliable cure with good patient satisfaction, where 2 cm of proximal muscle remains intact and in the presence of a 'normal' bowel habit, without urgency and in the absence of irritable bowel symptoms. (Grade C)
Fistulotomy not only involves completely laying open the fistula from one opening to the other and division of all the anal sphincter below it, but also identification of all secondary tracks and their adequate drainage. It results in healing in more than 95% of patients [92, 93] , but concerns regarding impairment of 'continence' inhibit surgeons and patients from selecting this option. The word 'incontinence' encompasses a wide spectrum, from the odd stain in the underwear, through inadvertent passage of flatus, to frank and devastating loss of stool with the prospect of a colostomy. Part of the consent process should include a detailed description of the various scenarios, rather than use the blanket-term 'incontinence'. Certainly, incontinence has a negative impact on quality of life [94] but so too does fistula recurrence [95] and an endless cycle of failure and recurrence is to be avoided as assiduously as faecal incontinence. Early on in a patient's surgical course even slight departure from a prior norm can be unacceptable; later on, after failed procedures, the trade for cure of the fistula is often welcomed.
Assessing the likely degree of impairment of continence associated with fistulotomy before it takes place is one of the great difficulties in proctology, and numerous studies have been directed at this question. Whereas division of the entire sphincter complex will result in total incontinence, preservation of the anorectal ring alone will prevent major incontinence in most patients [96] . It has been argued that progressively greater sphincter division leads to progressively greater impairment of continence. However, incremental functional loss has never been demonstrated and, as with liver resection, it is the volume of muscle left behind that is important and what determines continence.
When division of the internal sphincter alone is compared with division of both internal and external sphincter, the same degree of impairment of continence is seen [97] . Manometric data support this, demonstrating that maximum resting pressure decreases similarly whether the internal sphincter alone or both sphincters are divided [97] . In the same study, external sphincter division did lead to a reduction in maximum squeeze pressure, but as long as a minimum length of external sphincter is maintained a consistent level of impairment can be predicted, regardless of the degree of internal and/or external sphincter division performed. There is a one in three risk of flatus incontinence and marking of the underwear [92, 93] that is governed by the internal sphincter. The literature on lateral anal sphincterotomy for fissure supports this assertion [98] . There are specific groups of patients in whom the minimum amount of remaining muscle required is greater, as a consequence of looser/more frequent stool now, or the risk of it in the future, such as in irritable bowel syndrome or Crohn's disease, or in whom the length of muscle present will not permit further division, such as an anterior fistula in a woman [99] . Thus careful patient selection is crucial.
Determining the height of a fistula can also present a challenge. Some tracks travel obliquely cephalad, meaning that the internal opening gives a falsely low impression of the height of the track through the external sphincter [100] . It takes experience to be able to feel the internal opening of a fistula, but the information is vital as only with it can an estimate be made of how many centimetres of muscle will be preserved after laying open: the presence of a seton may help. The internal opening can be identified directly at operation, but if caudal/spinal anaesthesia has been used the proximal sphincter loses its tone and a estimation of length may be difficult. Light general anaesthesia, which can further be lightened, thereby inducing muscle contraction, serves to circumvent this problem.
Fistulotomy in acute anorectal sepsis
Findings
Immediate fistulotomy, although associated with a lower recurrence rate than simple incision and drainage, carries a risk of misjudgement of the depth of the fistula. (Level I)
Recommendations
Immediate fistulotomy should be undertaken only by experienced surgeons in patients in whom the internal opening is obvious without probing, and the fistula is 'simple'. (Grade A) A more conservative practice of simple abscess drainage in the majority of circumstances is safest. (Grade  GP) Two meta-analyses have considered the question of immediate fistula treatment at acute anorectal abscess drainage. Quah et al. [101] examined five randomized controlled trials (RCTs) and a subsequent Cochrane review added a sixth non-English language trial [102] . Both identified lower recurrence rates of anorectal sepsis (abscess or fistula) with immediate fistula treatment. This is perhaps not too surprising. In the five studies analysed by Quah et al. [101] , patients treated with abscess drainage alone presented with subsequent abscess or fistula in between 14% and 40% of cases, whereas immediate fistula treatment reduced recurrence to between 0% and 10%. Impairment of continence varied significantly in the immediate treatment arm across the studies, from as high as 40% in some to zero in others. Two of the five studies found a significant difference in impairment of continence between the two study arms, but at meta-analysis no such difference was seen. Both therefore advocate immediate fistula treatment. However, a more cautious approach may be preferable, particularly in less experienced hands.
The literature, including observational studies as well as these RCTs, consistently describes a lower 'recurrence' rate in patients in whom immediate fistulotomy is undertaken. But some 40% of patients with an abscess where culture revealed gut-related organisms never go on to develop a fistula [103] , which suggests potential overtreatment in a significant minority. Ho and Tang studied only patients with an abscess who had a demonstrable internal opening, and in the abscess drainage only arm, just 10 of 49 patients had recurrence [104] . What this means is that the remaining 39 patients (80%) would have been exposed to the risks of fistulotomy without benefit.
A reasonable compromise may be for an experienced surgeon to undertake immediate fistulotomy in simple fistulas when the abscess is recurrent and where drainage alone seems unlikely to resolve matters. But this relies on the detailed preoperative counselling, usually employed in the outpatient clinic, and which is less likely to be successful for a patient suffering a painful acute abscess and having little time to consider the options prior to urgent surgery.
Fistulotomy in inflammatory bowel disease
Findings
Most surgeons would avoid fistulotomy in a patient with Crohn's disease and an anal fistula. (Level III)
Recommendations
Careful consideration should be undertaken before performing fistulotomy in Crohn's disease, even for a 'low' fistula. (GP) Fistulotomy in Crohn's disease is uncommon, and a recent survey of UK surgeons indicated that around half would occasionally consider fistulotomy but only 3% did so frequently and more than a third would never do so [105] . van Koperen et al. [106] undertook fistulotomy in a group of patients with low fistulas in Crohn's disease with a recurrence rate of 17% and impairment of continence in two-thirds, both worse than the outcomes seen in idiopathic fistulas, which may explain the reticence of most UK surgeons to perform fistulotomy. This particular group of complex fistulas have been considered in more detail in another publication [105] .
Marsupialization
Findings
Marsupialization after fistulotomy is associated with a significantly shorter healing time (Level I) and a shorter duration of wound discharge. (Level I)
Recommendations
The wound edges of the laid open fistula track should be marsupialized to aid healing and reduce wound discharge. (Grade A) Marsupialization is a simple procedure which improves wound healing. It is also used as part of the wound shaping which some surgeons use to prevent early bridging and allow adequate drainage of the wound. Four randomized trials have demonstrated that marsupialization of the fistulotomy wound reduces time to wound healing [107] [108] [109] [110] . Ho et al. [108] demonstrated a faster healing time (6 vs 10 weeks, P < 0.001) in 103 patients randomized to fistulotomy vs fistulotomy with marsupialization. A higher squeeze pressure was also seen in the marsupialized group, but the clinical relevance of this is unclear. Pescatori et al. [110] studied 46 patients in the same way and found less bleeding as well as a quicker reduction in wound size in the marsupialized group. More recently, Jain et al. [109] randomized 40 patients to fistulectomy or fistulotomy with marsupialization, demonstrating faster wound healing (around 5 weeks vs around 7, P = 0.003) and earlier cessation of wound discharge. Chalya et al. [107] found similar results in 162 patients randomized between the same procedures.
Setons
The evidence supporting the use of setons in the management of anal fistulas was comprehensively reviewed in the original position statement on anal fistula [1] . Essentially a seton can be used in three main ways in the treatment of an anal fistula, with myriad variations of technique between published series. The seton can be inserted and tied loosely over the sphincter to drain the track and allow sepsis to settle before it is removed, in the hope that the fistula will heal (loose seton). The seton can be used to divide the sphincter muscle slowly to eradicate the fistula (cutting seton) and the seton can be used as a long-term drain to provide palliation of symptoms from the fistula, where other techniques are deemed unsuitable.
Loose seton
Findings
A loose seton, used as sole treatment, results in fistula healing in only a small proportion of patients. Higher healing rates are achieved by staged fistulotomy after a period of seton drainage. (Level III) A loose seton can be used to treat 'high' and complex anal fistulas with low risk to diminishing anal control. (Grade B) A number of series of patients treated with a loose seton continue to be reported, often with subtle variation in technique and all highlighting the relative safety of this technique as regards alteration in anal control. However, convincing evidence of fistula healing following simple removal of a loose seton is scant, and often an additional procedure is required to achieve fistula healing. Galis-Rozen et al. [111] reported a series of 77 patients, 17 of whom had Crohn's disease and were treated with a loose seton alone. Of the 60 patients with non-Crohn's fistulas, only 4 healed without further surgery and 20 (46%) healed following second-stage fistulotomy. However, a similar proportion of patients either had recurrence or did not heal following seton placement, possibly reflecting the complexity of fistulas included in this series. In a similar manner, Lim et al. [112] described an intriguing modification of the loose seton technique. The primary track was re-routed into the intersphincteric space, by dividing the mucosa and internal sphincter below the internal opening and placing a seton around the external sphincter in the intersphincteric plane, before closing the internal opening, mucosa and divided internal sphincter over the seton. Fifty-three patients were treated by this technique, with a reported recurrence rate of 13% and incontinence reported by two patients. However, follow-up was mostly by telephone contact and no clinical assessment was made to confirm healing of the fistula. An alternative approach was reported by Pinedo et al. [113] in 18 patients with transsphincteric fistulas. The external part of the track was laid open to the outer surface of the external sphincter and an internal sphincterotomy was performed to lay open the intersphincteric element of the track. A loose elastic seton was inserted in the remaining track through the external sphincter and removed when the internal opening had migrated to the anal verge. All setons were eventually removed after a median of 4 months; however, it is not clear how many fistulas healed, although there was deterioration in anal control reported. Subhas et al. [114] used a silk seton as a loose seton, which the patient was instructed to rotate through 360°in each direction on a daily basis. Twenty-four patients were followed for a mean of 45 months (but only by questionnaire and telephone interview), with 18 (75%) fistulas healing, 9 once the seton extruded spontaneously and 9 after low fistulotomy of the residual track: two patients developed incontinence of liquid stool only. Kelly et al. [115] followed a series of 200 patients treated with a polybutylate (Ethibond TM ) suture, with a recurrence rate of 6% and a low rate of incontinence.
However, follow-up was short (6 months) and detail of how changes in anal control were defined and assessed was lacking. Furthermore, although the loose seton controlled symptoms, most patients ended up requiring a second procedure to lay open the residual fistula track. Follow-up is not described in any detail and four patients (6%) were said to have experienced 'minor' incontinence.
Cutting (tight seton)
Findings
A tight seton inserted into a transsphincteric fistula will result in healing in upwards of 90% of patients. There is some risk of diminishing anal control that is influenced by the height of the internal opening and the amount of muscle encompassed in the seton. A tight seton has been used where a surgeon is unwilling to perform fistulotomy because it is thought that too much sphincter will be divided in the process and the risk of incontinence is high. A variety of techniques have been described, all with the same principle, namely slow division of the sphincter encompassed by the seton, with progressive caudal migration of the track and eventual extrusion of the seton. Much is made of the theory that this slow division with a foreign material generates fibrosis around the sphincter as it is divided, limiting separation of the sphincter ends and healing of the muscle cephalad to the seton as it descends the anal canal. This is in contrast to the springing open of the sphincter ends that occurs with primary fistulotomy. Attractive as this theory sounds, there is little or no evidence to substantiate improved sphincter morphology and function over immediate fistulotomy. Anecdotal comparison of ultrasound appearances of the sphincters after cutting seton suggest less sphincter separation than after fistulotomy, but it is uncertain if like is being compared with like [116] . Rosen and Kaiser [117] used data from Ritchie et al. [118] to demonstrate an association between the rate of incontinence and the interval between seton tightening, which they interpreted as supporting evidence that slow sphincter division preserves sphincter function. However, this requires a large leap of faith, as the data used were very heterogeneous, with different definitions of incontinence and periods of follow-up.
Evidence in favour of the use of a cutting seton is still based on case series, and no specific randomized trial of tight setons vs other surgical options has been performed. Most studies suffer from a number of flaws, usually involving the definition of end-points, limited follow-up and low numbers. A variety of different materials have been used as tight setons, including silk [119] , rubber bands, rubber surgical glove [116, 120] , silastic vessel sloop [121] and electrical cable tie [122] . Each modification is designed to make tightening the seton simple as well as avoiding the need for a general anaesthetic. Similarly, some authors perform internal sphincterotomy prior to seton insertion [123, 124] and others encompass both the external and internal sphincters in the seton, after removing skin and anoderm beneath the seton [116] . Whichever technique is employed, the internal sphincter will eventually be divided by the seton as it cuts through the fistula track and overlying sphincter. Vial et al. [123] performed a meta-analysis on a number of case series looking at recurrence rates and alteration in anal control after use of a cutting seton, with and without sphincterotomy at time of seton insertion. They concluded that recurrence rates were similar (at less than 5%), but overall incontinence was higher after sphincterotomy (25%) than after seton insertion without sphincterotomy (6%). However, these results should be interpreted with considerable caution as the studies were very heterogeneous, with different follow-up periods and different methods of assessing changes to incontinence.
Raslan et al. [119] collated 51 patients treated with a tight silk seton, with a recurrence rate of 10% and incontinence to flatus of 16% and liquid stool of 6%. However, details as to the anatomy of the fistulas treated and how continence was assessed are absent and follow-up duration was not specified, but was likely to have been short. A similar study by Kamrava et al. [125] used silk, but tightening of the seton was controlled by the patient. Recurrence was 10% and only 1 of 47 patients was reported to have new problems with control, although definitions used for assessing control were loose and follow-up was short. Using a thin electrical cable tie as a seton is intriguing: Memon et al. [122] reported a series of 79 patients with transsphincteric or suprasphincteric fistulas, with a recurrence rate of 5% and no reported change in continence. However, no details were given as to the level of discomfort experienced by the patients, who required on average six tightenings of the seton and an average of 12 weeks for healing to occur. Hammond et al. [121] used a silastic vessel and nerve sloop as a 'snug' seton in a series of 29 patients. The seton cut through the enclosed tissue in 15 patients, but 14 patients required a superficial fistulotomy to finally remove the seton. There were no recurrences identified, and 10 patients (34%) experienced early minor incontinence, which persisted in 4 of 16 patients followed for a median of 42 months. Leventoglu et al. [120] used a rubber glove as a 'hybrid' seton; this was not tied as tightly as a traditional cutting seton with the same intention as Hammond et al. [121] . Side tracks were dealt with by a modified Hanley technique, using Penrose drains. With this technique there was one recurrence over a mean follow-up of 20 months and no significant change in the Cleveland continence score. Ege et al. [116] used the cuff from a rubber glove as a 'hybrid' seton, tied snugly over the denuded external sphincter following internal sphincterotomy. They followed 128 patients, with the seton extruding after a mean of 19 days, suggesting that many fistulas were low. Complete healing occurred at 3 months in all patients and only two patients returned with a recurrent fistula after a minimum of 12 months' follow-up. However, in common with other studies, it is unclear as to how tightly the seton was tied over the sphincter. Izadpanah et al. [124] described a technique they called a 'pulling seton' in a large series of 201 patients in whom they divided the internal sphincter and the external part of the fistula, before tying a seton over the remaining external sphincter muscle. The patient was instructed to tug on the seton four times a day. Using this technique, they reported a recurrence rate of 5% and no permanent gas or faecal incontinence. However, follow-up was short and postoperative assessment of continence was limited. Rosen and Kaiser [117] reported on 121 patients with a transsphincteric fistula treated by tight seton. Initial healing occurred in 90% of patients, rising to 98% after further surgical procedures. Interestingly, 17 patients with preexisting continence problems improved following surgery, indicating that the presence of a fistula can cause continence problems (possibly by discharge through the track). Only eight patients developed new problems with anal control. These excellent results should be interpreted with some caution as follow-up of these patients was short (mean 5 months).
In summary, a variety of materials have been used as a cutting seton, with most series reporting successful healing of the fistula and recurrence rates of the order of 10% after short-term follow-up. It is uncertain if internal sphincterotomy is a necessary part of the procedure. It is likely that sphincter division (even slow division) will inevitably lead to some diminution in anal control, which may not become apparent immediately. Ritchie et al. [118] collated a large number of series and calculated an average incontinence rate of the order of 12%.
Advancement flaps
Advancement flap surgery is a well-established technique with reliable outcomes in experienced hands. The technique should be considered in patients in whom fistulotomy would result in a compromise to continence that would be deemed unacceptable to the patient, and with a track morphology that is likely to yield success. An advancement flap may also be used to close an anorectal or recto-urethral fistula. As well as disconnecting the fistula from the gut, a flap technique is effective as it brings a layer of healthy native tissue to cover the internal opening, following control of sepsis. Adequate vascularity of the flap and tension-free anastomosis, placed well beyond the site of the (excised) internal opening, are key to success. Advancement flaps can be taken from the rectum (transanal advancement flap) or from the perianal skin (cutaneous advancement flap). Also described are the transanal sleeve advancement flap (TSAF) and the Delorme'sstyle advancement flap. This is similar to the TSAF but, as in the Delorme's procedure for rectal prolapse, after mucosal mobilization the muscle wall is advanced and sutured down to the internal anal sphincter distal to the internal opening of the fistula. This procedure is facilitated by internal intussusception and would not be a tension-free repair without it [126] . The presence of internal intussusception or perineal descent may facilitate advancement flap repair.
A number of factors have been identified as risk factors for failure of an advancement flap procedure. These include, smoking [127, 128] , a flap for a recurrent fistula [127] , Crohn's disease [129] , horseshoe abscess [130] and high BMI [131] . Differing study populations may explain heterogeneity in the significance of risk factors identified in different studies.
Transanal advancement flap
Findings
The success rate of transanal advancement flap is of the order of 60%. (Level III)
Recommendations
Transanal advancement flap can be used to treat an anal fistula where simple fistulotomy is thought likely to result in unacceptable impairment of continence. (Grade B) The transanal rectal advancement flap procedure has several advantages over other treatments for anal fistula. Division of the external sphincter is avoided with less risk of impairment of continence, and defects of the contour of the anal canal, such as a keyhole deformity, are avoided and healing is quicker than after fistulotomy. Additional procedures can be incorporated into the operation, such as sphincteroplasty, without the need for a protective colostomy. Failure of the repair does not usually lead to worse symptoms, although the internal sphincter at the level of the anorectal junction will have been disrupted to a certain extent and the anal canal will be somewhat more rigid as a result of scar tissue. This could result in functional impairment.
Relative contraindications to the transanal rectal advancement flap procedure include: the presence of proctitis -especially in patients with Crohn's disease; undrained sepsis and⁄or persisting secondary tracks; an anorectal fistula with a diameter > 3 cm; malignant or radiation-related fistula; a fistula of less than 4 weeks' duration; and an associated stricture of the anorectum [132] . Stricture, tissue loss and scarring of the anorectum may impair the surgeon's access and may make flap repair technically impossible.
The surgical technique for endoanal advancement flap procedures has been described in earlier publications [133] [134] [135] and was summarized in the previous position statement [1] . Whilst many surgeons would use mechanical bowel preparation prior to surgery, and consider the use of a defunctioning stoma to cover the procedure, there is no evidence base to support these approaches. A semi-circular flap is most commonly used as this avoids ischaemia at the corners. The majority of authors describe a U-shaped flap, while a minority use an inverted Ushaped flap. The flap consists of mucosa, submucosa and a varying degree of circular muscle from none to the full rectal wall thickness, depending on the author. There has been limited evidence from individual studies to support the logical assertion that more muscle means greater vascularity and therefore success, at the cost of a greater risk of impairment of continence, but pooled data from a recent meta-analysis suggest that this is correct [136] .
The transanal sleeve advancement flap procedure
The TSAF takes the concept of flap advancement one step further by mobilizing the circumference of the anal canal. It has been used for a subgroup of patients with severe complex fistulas associated with Crohn's disease [137] . The technique is similar to the transanal flap procedure described above, but in addition a 90-100% circumferential incision is made at or just below the dentate line to create a sleeve of the full thickness of the bowel wall. This is then mobilized proximally into the supralevator space until sufficient mobility is achieved to allow the flap to be advanced distally into the anal canal without tension. Its distal edge is then sutured with absorbable sutures to the epithelium of the anal canal below the level of the internal opening. This technique may offer an alternative in selected patients with fistulation in Crohn's disease without proctitis, for whom the only alternative is proctectomy with permanent stoma.
The cutaneous advancement flap procedure
Findings
The cutaneous advancement flap procedure has a similar success rate to endoanal flap, but the theoretical risk of avoiding ectropion formation. (Level III)
Recommendations
The cutaneous advancement flap procedure is an alternative to rectal advancement flap repair of a high fistula. (Grade B) The cutaneous advancement flap appears to have a similar success rate to endoanal flap procedures, with the theoretical advantage that by moving skin into the anal canal, mucosal ectropion is avoided [138] [139] [140] [141] . The technique for the procedure has been described elsewhere [138] [139] [140] [141] .
Postoperative management of flap procedures
There is no consensus on the role of anti-diarrhoeal agents or antibiotics in the early postoperative period. Normal anal wound management should be carried out.
Fistula recurrence after advancement flap procedures
It is difficult to compare published series as there is often great variation in the type and complexity of fistula, and the methods of repair. Long-term followup is essential for assessing recurrence accurately. Advancement flap procedures are safe. Early case series suggested efficacy in around 70% of patients [132] [133] [134] [138] [139] [140] [141] [142] [143] [144] . However, more recent randomized controlled trial data, often vs the anal fistula plug, and larger series, suggest healing in a smaller proportion, perhaps of the order of 50-60% [145] [146] [147] . A recent multicentre randomized trial of 94 patients from Scandinavia found a primary success rate (defined as clinical healing), at a median of 12 months of follow-up, of 62% of 40 patients. A full-thickness flap was used and patients had a single, non-complex high transsphincteric track and after only a single previous fistula operation (probably seton insertion). The comparator group, treated with a fistula plug, achieved clinical success in only a third of patients. MRI confirmation of healing was not reported in either arm [148] . This study represents a robustly performed assessment of transanal rectal advancement flap surgery in wellselected patients, and is a realistic report of the technique. A recent meta-analysis including 26 studies and 1655 patients indicated an increasing success rate (avoidance of recurrence) with increasing thickness of the flap raised, although there was significant heterogeneity between studies [136] . The pooled recurrence rate was 21%, but ranged from 0% to 47%. Core out vs curettage of the track did not influence outcome.
Continence impairment
There is great heterogeneity in how continence is assessed following advancement flap surgery. Early studies found little impairment of continence but some authors suggest minor incontinence may occur in around a quarter of patients [149] . Meta-analysis suggests a greater likelihood of continence impairment with full-thickness flaps (20%) than mucosal or partial thickness flaps (10%), although the impairment was generally minor [136] .
Fibrin glue
Findings
The use of fibrin glue to treat anal fistulas is associated with variable success, but does not threaten continence. It remains uncertain as to which fistulas are suitable for fibrin glue treatment. Success (fistula healing) is low when the fistula track is short. (Level I)
Recommendations
With variable and mostly low rates of healing, fibrin glue is not recommended for routine use in anal fistulas, but may be considered where other surgical options are not feasible. (Grade C)
Various autologous and commercial preparations of fibrin glue have been used to treat anal fistulas. Autologous glues are formed from the patient's own blood, whilst commercially available glues are a mixture of clotting factors, aprotinin and calcium (Beriplast; CSL Behring, Pennsylvania, USA; Tisseel; Baxter Healthcare, Deerfield, Illinois, USA), or are synthetic glues, such as cyanoacrylate (Glubran; GEM SRL, Viareggio, Italy). The glues are applied to fill the fistula track and provide a bridge for fibroblasts and stromo-vascular cell ingrowth to produce healing. Their ease of use, minimal risk to continence and repeatability make them an attractive option, especially in patients at high risk of sphincter dysfunction [150, 151] .
A wide range of healing rates with fibrin glues have been reported, ranging from 14% to 94% [152, 153] . Variability in disease complexity, fistula anatomy and surgical technique makes comparison of the results from randomized trials difficult to interpret [154] [155] [156] . A meta-analysis has not shown any statistical difference with the use of fibrin glue, compared to other conventional surgical treatments, in terms of fistula recurrence or incontinence [157] .
Some authors have reported better healing rates in longer tracks, suggesting that shorter tracks (< 3.5 cm) are less likely to retain the glue [155, 158] , but this has been contradicted in other reports [159] [160] [161] . Technical errors have been suggested for failure, including inadequate curettage and washout to remove all infected and epithelialized tissue [155, 161, 162] , or incomplete filling of the track with the glue to ensure occlusion [155] .
Like other fistula treatments, recurrence rates with fibrin glue increase with the length of follow-up. A longterm follow-up study showed that up to 26% of patients who were symptom free at 6 months went on to develop recurrence at an average of 4.1 years [163] . However, on several occasions the recurrence was at a different site, suggesting that a new fistula had formed. The highest probability of failure appears to occur in the first 6 months following treatment, so 6 months should be the minimum follow up period [152, 161, 164, 165] .
A multicentre trial randomized patients to fibrin glue or seton treatment for transsphincteric fistulas and showed a 38% healing rate in the fibrin glue group, compared with 87% in the seton group [150] . Patients who had a recurrence after fibrin glue were further randomized to repeat glue treatment or a loose seton. A further 50% healed with repeat glue treatment. Notably, there was a significant worsening in the Cleveland Clinic continence score in the seton group. Many studies have investigated the use of repeat glue application to increase healing rates, even up to four applications [166] . A prospective study of fibrin glue for simple transsphincteric and intersphincteric fistulas showed that repeat glue treatment decreased the overall recurrence rate from 23% to 7.6% [167] . Conversely, other authors have reported that repeated applications of fibrin glue are unlikely to succeed [168] and other studies have shown an adverse outcome when fibrin glue is combined with an endorectal advancement flap [169] .
Various strategies have been suggested to improve the healing rates with glues. Local sepsis should be eradicated with the use of preoperative setons, the track should be thoroughly curetted and the track irrigated with either saline or hydrogen peroxide. Preoperative bowel preparation has not consistently shown a benefit. Suturing the internal or external openings shut has been advocated, but not shown to confer a significant benefit [152] .
It has been suggested that high failure rates with the glue may be a consequence of the glue not being retained in the fistula track [170, 171] . To overcome this, some authors have recommended the use of stool softeners and avoiding straining and exercise in the postoperative period, although there are no data to support this. Other explanations for failure of fibrin glue include early resorption/degradation within 5-10 days of application, providing insufficient time for established healing [165, 171] . A Phase I trial using Permacolâ glue, which incorporates fibres suspended in fibrin glue to provide a physical scaffold for host cell proliferation after glue absorption, has shown promising results, but more, randomized, data are required [165] . Newer autologous fibrin sealants have not shown any increased efficacy compared with conventional glues, with healing rates of up to 40% [172] . Research continues into the use of stem cell autologous suspensions for fistula application and the ADMIRE CD study used fibrin glue as the scaffold for allogeneic mesenchymal stem cell treatment of Crohn's anal fistulas [173] . This may represent the main role for fibrin glue in the future.
Fistula plugs
Findings
The initial reported high success rates of anal fistula plugs have not been maintained in later series, but, similar to fibrin glue, anal fistula plugs do not threaten continence. It remains uncertain as to which fistulas are best suited to fistula plug treatment. (Level I)
Recommendations
Accepting that rates of healing are variable, an anal fistula plug is an option for treating transsphincteric fistulas, especially where surgical options are considered to have a significant risk of jeopardizing continence. The additional cost of the plug should be taken into account when considering this surgical treatment. (Grade C) Anal fistula plugs (AFPs) are bioprosthetic or synthetic materials used to occlude the fistula track, blocking the internal opening and preventing faecal material from entering. They provide a physical scaffold for ingrowth of host regenerative and immune cells to promote healing and repair. The plugs degrade over a period of several weeks, by which time the repair process is established.
Types of plug. Several fistula plugs have been developed commercially, but the BioDesign Surgisisâ Anal Fistula Plug (Cook Medical, Bloomington, Indiana, USA), composed of acellular, lyophilized porcine intestinal submucosa, is the most established. Other plugs include the GORE Bio Aâ Fistula Plug (Flagstaff, Arizona, USA), a composite of polyglycolic acid and trimethylenecarbonate synthetic polymers [174] , which has now been withdrawn by the manufacturer, the Pressfitâ plug (Deco Med s.r.l., Venice, Italy), which is made from acellular dermal matrix, and the Curaseal AFâ device (CuraSeal, Inc., Santa Clara, California, USA), which incorporates a silicone disc to reinforce occlusion of the internal fistula opening. Secure anchoring of the plug at the internal opening is a critical feature in the design of all these plugs. Surgical technique. Reported success rates for fistula healing with plugs vary, ranging from 24% to 88% [175] , reflecting differences in patient selection, plugs used, surgical technique, definition of healing and length of follow-up. In 2007, a Consensus Conference was held to establish uniformity in the indications and techniques for insertion of the Cook Medical fistula plug [176] . It concluded that all types of ano-cutaneous fistula were suitable for plug treatment, with transsphincteric fistulas being the ideal indication. Emphasis was placed on the prior control of associated sepsis and the use of seton drainage for 6-12 weeks preoperatively. Debridement or curettage of the track was discouraged, although gentle brushing to deepithelialize the track was subsequently recommended, with saline or hydrogen peroxide irrigation being optional. Secure suturing of the plug to the internal opening/internal sphincter was considered important to prevent early extrusion of the plug, which had been reported as a cause for failure in some studies [177] . There was no evidence to support the routine use of a rectal mucosal flap to cover the plug. Suturing of the plug has been facilitated by modification of the original plug design to incorporate an internal 'button'.
Initial encouraging results from Johnson et al. [178] reporting closure rates of up to 87% have not been reproduced in later studies, which have presented mixed results. A randomized trial comparing the fistula plug with endorectal advancement flap (ERAF) was closed prematurely due to a high incidence of recurrence in the plug arm [179] . In another RCT, comparing an acellular dermal matrix (ADM) plug vs ERAF, a healing rate of 82% was reported in the ADM group, with lower rates of recurrence (ADM plug 4% vs ERAF 28%) [180] . A subsequent meta-analysis comparing the plug with ERAF failed to show any difference in recurrence rates or complications [181] . However, a recent robust multicentre RCT of 94 patients with a transsphincteric fistula demonstrated clinical healing at 12 months in only 38% (15 of 44 patients) treated by collagen plug, compared with 66% (27 of 41 patients) treated by ERAF [148] .
A potential disadvantage with the plug is the cost of the device, but this may be offset by a shorter hospital stay. In a study comparing fistula plug against ERAF, healing rates were similar, but the costs associated with ERAF were higher due to a longer duration of hospital stay [182] .
In a recent UK multicentre study (the NIHR FIAT trial) 152 patients were randomized to receive the Cook Biodesign fistula plug and compared with 152 patients receiving surgeon's preference [cutting seton, ERAF, fistulotomy or ligation of intersphincteric fistula track (LIFT)]. Similar clinical fistula healing rates were observed at 12 months' follow-up (plug 54% vs surgeon's preference 57%). Early plug extrusion remained a problem, despite the adoption of best surgical technique, occurring in 15% of cases. Rates of incontinence were low in both groups and there was no statistical difference in quality of life as measured by the FIQoL and EQ-5D scoring systems. Complications rates were similar between the two groups, with the exception of increased early postoperative pain in the plug group, presumably associated with suturing to the internal anal sphincter.
The fistula plug has been successfully used in combination with other procedures, including the LIFT procedure. In a large, multicentre RCT, the LIFT-plug procedure was found to result in statistically significant higher healing rates compared with LIFT alone (LIFTplug 94.0% vs LIFT 83.9%; P < 0.001) [183] .
Most studies have included variable follow-up after surgery, ranging from 3 to 12 months. A long-term follow-up study, using MRI to assess fistula healing at 12 months after plug insertion, showed radiological evidence of a persistent fistula in up to 21% of patients, suggesting that reports of fistula healing at 12 months are likely to be an overestimate [184] .
Benefits in favour of the fistula plug include ease of use and lack of complications. No differences in complication rates have been reported between ERAF and AFP [181] , with documented complications including sepsis/abscess, recurrence and constipation [183, 185, 186] . Unlike some other techniques, no study has reported a detrimental effect to continence following use of a plug. Thus, the fistula plug is an option for treating a transsphincteric fistula. Uncertainty in healing efficacy is counterweighed by the lack of detrimental effect on continence. The cost of the device might be offset by shorter lengths of hospital stay.
Novel techniques
Findings
A number of novel surgical techniques for anal fistulas have been developed over the last 10 years. These include the LIFT procedure, lasers, clips, videoassisted anal fistula treatment (VAAFT) and autologous adipose-derived stem cells. Evidence of efficacy is scant and largely confined to personal series (Level III evidence) with a paucity of RCTs performed to date, and what is available is confined to the LIFT procedure. Whilst initial work on other techniques looks interesting, with minimal adverse events reported, long-term follow-up needs to be reported as many institutional series only document short/medium follow-up, functional outcome data are limited and few patient-reported outcome data are available. A degree of standardization is required in approaches using multiple concurrent treatments. Randomized evidence is needed before these new techniques will challenge conventional approaches.
Recommendation:
The LIFT procedure is an option for treatment of a transsphincteric fistula, with or without insertion of a bioprosthetic graft in the intersphincteric space. (Grade B)
It is too early to recommend the routine use of other novel treatments for anal fistula. (Grade C)
The LIFT procedure. The LIFT procedure was first reported in 2007 [187] , when healing was seen in 17 of the first 18 patients reported. The principle is essentially to make an incision in the intersphincteric groove, ligate the intersphincteric fistula track, remove the fistula track and then curette it from the external opening. The external sphincter muscle defect is closed, as is the intersphincteric wound.
Three RCTs have been reported [183, 188, 189] (Table 2) . One only compared LIFT with a modification of LIFT, rather than a standard treatment, whilst the other two compared LIFT with a mucosal advancement flap. In addition, 18 case series have been reviewed [187, [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] (Table 3) . A number of series reporting fewer than 10 patients were disregarded for the purposes of this position statement.
Madbouly et al. [189] randomized 70 patients to either LIFT or a mucosal advancement flap. Primary healing was achieved in 33 (94%) patients undergoing LIFT compared with 32 (91%) patients undergoing a flap repair. Median healing times were 22.6 and 32.1 days, respectively. After follow-up of 1 year, a successful outcome was achieved in 26 (74%) of the LIFT group compared with 20 (66%) in the advancement flap group (P = 0.58), highlighting the importance of longterm follow up in fistula surgery research. There was no significant difference in continence scores in this study.
A similar, but smaller, study randomized 25 patients to LIFT and 14 to anorectal advancement flap [188] . All patients had seton inserted prior to definitive surgery. Recurrences were seen in 2/25 and 1/14, respectively. The authors concluded that LIFT was simple and safe, took significantly less time than a flap and patients returned to work earlier.
Sileri et al. [194] reported 26 patients with complex fistulas, 19 of whom were healed at a minimum of 16 months following LIFT. The recurrences occurred between 4 and 8 weeks following surgery. They defined 'complex' as any track that was deeper than 30% of the external sphincter, anterior fistula in women, recurrent fistula or preexisting incontinence. Only two patients had previously had a loose seton inserted prior to the LIFT procedure. Another series of 40 patients with transsphincteric fistulas deemed to be inappropriate for fistulotomy underwent LIFT [205] . Success rates of up to 74% were noted, although follow-up was short (a mean of 18 weeks).
Ooi et al. [199] reported 25 patients who had undergone LIFT. Ten of them had developed recurrence after previous fistula surgery. The primary and secondary end-points were cure rate and degree of incontinence, respectively. Primary healing was observed in 17 (68%) patients at a median of 6 weeks. Seven patients had recurrence of their fistula, which presented between 7 and 20 weeks' postoperatively. There was no reported incontinence. Liu et al. [204] A recent large series (167 patients) reported a success rate (healing) of 94% at a median follow-up of 12 months [198] . The majority of fistulas were transsphincteric [150] , and a number were recurrent [33] . Ten patients who developed a recurrent fistula were managed with a repeat LIFT procedure. Schulze et al. [196] performed LIFT on 75 patients between May 2008 and June 2013. All had undergone an initial procedure that involved drainage of sepsis, insertion of a loose seton and partial fistulotomy. There were nine recurrences, at a mean follow-up of 14.6 months, all of which were treated with repeat LIFT and biograft or anorectal advancement flap. There were no subsequent recurrences. Recurrences were related to fistulas with multiple tracks. Only one patient reported a change in continence.
An attempt has been made to determine whether LIFT is more effective in distinct fistula sub-types [197] . LIFT was performed in simple transsphincteric (five), complex fistulae (six) and recurrent cases postfistulotomy (six). The overall success rate at a mean follow-up of 11 months was 53%. Healing rates in the three groups were four out of five, three out of six and two out of six, respectively. These numbers are too small to draw any conclusions, but intuitively LIFT should be more likely to succeed in less complicated fistulas (as is the case for all fistula treatments). There is general consensus that the presence of multiple tracks, diabetes mellitus, perianal collections and long tracks are all associated with a higher chance of failure of LIFT.
LIFT has been employed as an alternative to fistulotomy in patients with low transsphincteric fistulas [190] . Healing was seen in 18/22 patients recruited at a median follow-up of 19.5 months. The four unsuccessful cases were treated with fistulotomy. Although there was no comparison with patients with similar fistulas undergoing fistulotomy as sole treatment, the authors reported a final healing rate of 100% and no alteration in continence, which was assessed prospectively.
A Chinese group recently reported on 43 patients with 'complex' fistulas treated by LIFT, all of whom were followed up for more than 1 year [201] . Healing of the fistula was seen in 36 of 43 (84%) patients; failure, when seen, occurred a mean of 8.6 weeks after the original procedure. In this series, eight patients had dehiscence or infection at the site of the intersphincteric wound, with five patients requiring laying open. This complication is probably commoner than reported in many series.
Modifications to the LIFT procedure have been described. The Bio-LIFT procedure, for example, involves placing a biograft (usually a piece of collagen mesh) in the intersphincteric space following ligation of the intersphincteric fistula track. Success was reported in 11 of 16 (63%) fistulas treated, at a median follow-up of 26 weeks [192] . A randomized trial comparing the two approaches in 235 patients reported healing rates at 6 months of 94% in the LIFT + biograft group, vs 84% in the LIFT group alone [183] . The authors reported that the addition of the graft had the advantage of higher healing rates, decreased healing time and a lower early postoperative pain score. Another modification involves making a lateral incision from the external opening to the intersphincteric groove, ligating the fistula track within the intersphincteric space and complete excision of the external part of the fistula [195] . In a series of 39 patients treated in this way and followed for a mean of 15 months, 34 (87%) achieved healing. There was no change in continence, as measured by the Cleveland Clinic score preoperatively and at 6 months postoperatively. An alternative approach is to de-roof the fistula from internal opening to intersphincteric groove and ligate the fistula track, while at the same time preserving the external sphincter. This modified LIFT was performed on a series 56 patients, with an overall cure rate of 71%. True recurrence (5%) was much less frequent than simple failure of the technique and persistence of an active fistula track after the operation [202] . LIFT has been used as treatment for recurrent fistulas [191] . Fifteen patients with recurrent transsphincteric fistulas were followed up for 8-26 months (median 13.5 months). At the end of follow-up, six patients still had evidence of fistula, either persistence of the original fistula (four patients) or recurrence (two patients). LIFT has also been used in selected patients with Crohn's disease, with 8 of 12 reported to be healed at 12 months [200] .
To conclude, to date there are a few randomized studies as well as number of case series that attest to the potential efficacy of LIFT. LIFT appears to be associated with less functional compromise than some traditional treatments of transsphincteric fistulas, although recurrence/persistence rates are probably similar. One of the advantages of the LIFT procedure is that of secondary success. Where a genuine downstaging of the fistula from transsphincteric to intersphincteric takes place in a proportion of failures, allowing laying open of this intersphincteric fistula, preserving the external sphincter which would have been involved originally [207] . Future work should focus on comparison with standard treatments, paying particular attention to comparing similar fistulas and focusing on deeper fistulas, where conventional treatments may be more problematic as regards functional outcome.
Stem cell therapy. Autologous adipose-derived stem cells may represent a novel treatment option for complex fistulas, although as yet there is insufficient evidence to attest to its efficacy. As a technique it may be used in isolation or in combination with fibrin glue or advancement flaps. It has been used in patients with Crohn's disease. Allogeneic, expanded, adipose-derived stem cells have been used in a randomized, multicentre, double-blind placebo-controlled study involving 212 patients [173] . The primary end-point was remission at 24 weeks. In the intention-to-treat analysis 53/107 (50%) receiving stem cells achieved this, compared with 36/105 (34%) in the placebo arm (P = 0.024). A separate multicentre, single-blind trial randomized 200 patients to stem cells alone, stem cells in combination with fibrin glue or fibrin glue alone, following closure of the internal opening [208] . There was no significant difference in healing rates between any of the groups, which were 40-50% at 12 months' follow-up: no serious adverse events were reported. A further small case series of seven patients reported healing rates of five out of seven at 6 months and four out of seven at a median of 46 months [209] . Long-term results of a Phase II trial in patients with Crohn's disease reported healing rates of 75% at 24 months' follow-up [210] . Recently reported work looked at whether autologous mesenchymal stem cells could heal fistulas in Crohn's disease if applied in a bioabsorbable matrix [211] . At 6 months 10/12 patients had complete clinical healing. It is too soon to comment on the role of this complex treatment in the routine management of anal fistulas.
Laser therapy. Laser therapy was described as a treatment option for anal fistula in the 1980s [212] , and more recently with a radial emitting laser probe [213] , the principle being to destroy epithelial cells lining the fistula track. It has been trialled in combination with fibrin glue [214] , although more recent work, using the laser in isolation, demonstrated healing in 9 of 11 patients at a median of 7.4 months [213] . In this study, the internal opening was closed using a flap in combination with laser ablation. A further larger study, recruiting 45 patients, found healing in 32 (71%) at a median of 30 months [215] . All patients underwent placement of a loose seton prior to surgery, and 35 patients had a history of previous fistula surgery. A retrospective review of 50 patients treated by laser ablation showed 'success' in 41 (82%) at 12 months' follow-up [216] , which was mostly by phone, consequently these results need interpreting with caution. Wilhelm et al. [217] reported a series of 117 patients treated with the radial fibre fistula laser closing (FiLaC TM ) device. Patients in this series were followed for a median of 25 months (minimum 6 months) with primary healing in 64% of patients. A repeat procedure was performed in 31 patients who failed initial treatment, with overall healing achieved in 88% of patients. The treatment was associated with minimal alteration in anal control.
At present, laser ablation of a fistula track is in its infancy, with evidence supporting its use confined to a few case series (Level II/III evidence). The best technique has not been established: for instance, is surgical closure of the internal opening necessary prior to laser ablation? Further larger studies, especially randomized trails against other sphincter-preserving techniques, are required to establish its role in treatment of anal fistulas.
Fistula clips. The principle of this technique is to debride the primary track and close the internal opening with a tightly applied metal clip. The most extensively investigated apparatus is the OTSCâ Proctology (Ovesco Endoscopy AG, Tu72074 T€ ubingen, Germany), which employs a nitinol clip. A recent case-series has demonstrated healing in 18 of 20 (90%) fistulas at 6 months [218] . This group consisted of 14 patients with a transsphincteric fistula and 6 with suprasphincteric fistulas, although details of the complexity of the tracks was not given. Two patients required removal of the clip as a result of delayed wound healing and discomfort. Another case-series of consecutive patients from a single institution used the OTSCâ in refractory cases of anal fistula following previous surgery [219] . Six of the 10 patients recruited had Crohn's disease. Seven patients' fistulas were healed at a median followup of approximately 8 months. The FISCLOSE trial is aimed at evaluating the efficacy and safety of a clip vs rectal mucosal advancement flap [220] . The aim is to recruit 46 patients to two centres. The primary outcome is healing at 3 months. Secondary outcomes include healing at 6 and 12 months, anal pain, faecal incontinence and quality of life.
In a similar way to laser ablation, clipping the internal opening of a fistula is at an early stage of evolution, with a few encouraging case series having been published (Level II/III evidence). Migration and pain, requiring removal of the clip at the request of patient, are significant risks that have been reported in the few studies which have been reported. Further larger studies, especially randomized trails against other sphincterpreserving techniques, are required to establish whether it has role in treatment of anal fistulas.
Video-assisted anal fistula treatment. Video-assisted anal fistula treatment (VAAFT) consists of a diagnostic and a therapeutic phase. In the former, a fistuloscope and obturator are used to identify the internal opening as well as any secondary tracks and/or abscesses. The scope is inserted through the external opening and a glycine-mannitol solution infused to enable opening of the primary track and advancement under direct vision. The therapeutic phase involves destruction and cleaning of the track using cautery and further irrigation. One of the principles is closure of the internal opening using a circular/linear stapler, OTSC or advancement/mucosal flap. Cyanoacrylate may be used to reinforce the closure of the internal opening, though the track must be left open to allow secretions to drain.
Work from Italy reported on 136 patients undergoing VAAFT over a 5-year period [221] . Ninety-eight patients were followed up for a minimum of 6 months. Primary healing occurred in 72 (73%) patients within 2-3 months of surgery, with no major complications seen.
Sixty-two patients were followed up for over a year, with healing noted in 52 (84%). A further study from Singapore reported on 41 patients treated with VAAFT [222] : all were cryptoglandular in aetiology, though low intersphincteric fistulas and patients with abscesses were excluded. A number of approaches were used to obliterate the internal opening -stapling, advancement flap and OTSC. Eleven patients had undergone previous fistula surgery. Overall primary healing was seen in 29 (71%) patients at a median follow-up of 34 months, with the best results seen with VAAFT in combination with the OTSC. This approach has also been used in patients with Crohn's disease in combination with an advancement flap [223] . Success in the 13 patients recruited was defined as closure of both internal and external openings, absence of drainage without requirement for intervention and no abscess formation. All patients had complex fistulae, five were on biological agents and four had a proximal stoma. At a mean follow-up of 9 months 9 of 11 patients, where VAAFT was technically possible, were deemed a success, and no deterioration in continence was observed. VAAFT has also been reported in a paediatric population [224] . Thirteen procedures were performed on nine children (mean age 9.6 years). One was associated with Crohn's disease, though only five were described as idiopathic. All patients who underwent a complete VAAFT (n = 8) were healed at 10 months.
VAAFT is another novel treatment that shows some promise, although it is far from clear which part of the treatment is important and whether the video element is vital to its success or whether thorough cleaning of the track and secure closure of the internal opening is equally successful, saving the investment in the video technology. Proponents argue that the diagnostic phase finds tracks that MRI has missed, although evidence to support this assertion is lacking. More detailed studies are required before this dilemma can be resolved and the role of VAAFT be defined.
Conclusions
Anal fistula continues to perplex surgeons, and in the 10 years since the first version of this Position Statement was published, a number of new treatments have been developed. Although many of these treatments show promise, it is too early to state whether they are superior to well-tried surgical treatments for anal fistula, which should continue to be the 'gold-standard' against which newer treatments are compared. Drawing conclusions for the literature remains difficult because the quality of publications is variable, with many studies having limited follow-up or poor definitions of endpoints. However, randomized trials are becoming more common and are to be welcomed. As well as focusing on surgical end-points (healing, alteration in anal control, etc.) future trials should also include data on patient-reported outcome measures.
